We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesLexaria Bioscience Corp

Lexaria Bioscience Corp

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
4.34 USD -0.30 ( 6.47%)
Last update at 2026-11-12T15:39:00Z
VOLUME
23431
Market Cap
6.76M

Momentum Score

…

Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. The company's DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, epilepsy, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, and oral products; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
4.02
Low
4.34
High
52 Week Price Range
2.98
Low
23.25
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Lexaria Bioscience Corp develops a proprietary oral delivery platform (DehydraTECH) to enhance absorption of lipophilic compounds including cannabinoids. Growth drivers include licensing and collaboration around its IP, further clinical validation of improved bioavailability, and potential adoption by pharmaceutical and consumer product companies, which may make the IP-focused model attractive.

Key risks are an early-stage unprofitable profile with limited revenue, reliance on positive clinical and licensing outcomes, regulatory uncertainty for cannabinoid-related uses, and competitive and execution risks typical of small-cap biotechs.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
4.64
Dividend Yield
-
Revenue TTM
0.19M
Revenue Per Share
0.13
Gross Profit TTM
0.19M
Debt / Equity
0.04
ROE
-162.77%
Net Debt
-1.69M
ROCE
-444.18%
Diluted EPS TTM
-4.57

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Income before tax -11.91M -5.81M -6.71M -7.38M -4.16M
Minority interest 0.01M 0.01M 0.05M 0.11M 0.16M
Net income -11.90M -5.80M -6.66M -7.27M -2.50M
Selling general administrative 4.35M 3.85M 3.06M 5.72M 4.97M
Gross profit 0.70M 0.46M 0.19M 0.18M 0.55M
Reconciled depreciation 0.09M 0.08M 0.15M 0.14M 0.15M
Ebit -11.91M -5.81M -6.31M -7.38M -5.69M
Ebitda -11.82M -5.73M -6.17M -7.24M -7.06M
Depreciation and amortization 0.09M 0.08M 0.15M 0.14M -1.38M
Operating income -11.88M -5.75M -6.53M -7.38M -5.69M
Other operating expenses 12.59M 6.22M 6.76M 7.64M 6.41M
Interest expense - - - 0.11M 0.00M
Interest income 0.00M 0.01M 0.04M - -
Net interest income 0.00M 0.01M 0.04M - -
Income tax expense - - 0.13M -0.11M -1.66M
Total revenue 0.71M 0.46M 0.23M 0.26M 0.72M
Total operating expenses 12.58M 6.21M 6.73M 7.57M 6.23M
Cost of revenue 0.00M 0.00M 0.03M 0.07M 0.18M
Total other income expense net -0.03M -0.06M -0.22M - 1.52M
Discontinued operations - - - - -0.02M
Net income from continuing ops -11.91M -5.81M -6.71M -7.38M -4.16M
Net income applicable to common shares - - - -7.27M -4.03M
Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Total assets 4.18M 8.87M 3.08M 7.83M 13.27M
Intangible assets 0.31M 0.52M 0.46M 0.49M 0.36M
Other current assets 1.33M 1.19M 0.55M 0.58M 0.32M
Total liab 1.57M 1.21M 0.40M 0.20M 0.20M
Total stockholder equity 2.99M 8.04M 3.04M 7.95M 13.27M
Other current liab 0.10M 0.69M 0.24M 0.09M 0.05M
Common stock 0.02M 0.02M 0.01M 0.01M 0.01M
Capital stock 0.02M 0.02M 0.01M 0.01M 0.01M
Retained earnings -63.46M -51.56M -45.76M -39.10M -31.83M
Cash 1.80M 6.50M 1.35M 5.81M 10.92M
Total current liabilities 1.49M 1.10M 0.27M 0.19M 0.15M
Current deferred revenue - 0.00M -0.23M - -
Net debt -1.69M -6.36M -1.19M -5.76M -10.82M
Short term debt 0.03M 0.03M 0.03M 0.04M 0.05M
Short long term debt - - - - 0.01M
Short long term debt total 0.11M 0.14M 0.16M 0.05M 0.10M
Other stockholder equity 66.50M 59.60M 48.80M 47.04M 45.09M
Property plant equipment - - - 0.37M 0.46M
Total current assets 3.47M 7.90M 2.20M 6.98M 12.44M
Net tangible assets - - - 7.46M 12.90M
Short term investments 0.17M 0.06M 0.13M 0.35M 0.83M
Net receivables 0.17M 0.15M 0.18M 0.20M 0.34M
Inventory - - 0.00M 0.04M 0.03M
Accounts payable 1.37M 1.06M 0.23M 0.06M 0.05M
Accumulated other comprehensive income -0.07M -0.02M - - -
Non currrent assets other 0.06M 0.06M 0.46M 0.49M 0.36M
Non current assets total 0.71M 0.97M 0.88M 0.86M 0.82M
Capital lease obligations 0.11M 0.14M 0.16M 0.05M 0.09M
Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Investments -0.24M -0.19M -0.17M -0.18M 0.19M
Change to liabilities - - - 0.05M -0.03M
Total cashflows from investing activities -0.24M -0.19M - -0.18M 0.19M
Net borrowings - - - -0.04M -0.07M
Total cash from financing activities 6.05M 10.32M 1.59M -0.04M 13.42M
Change to operating activities - - - -0.26M -0.19M
Net income -11.91M -5.81M -6.71M -7.38M -4.19M
Change in cash -4.70M 5.15M -4.46M -5.10M 9.62M
Begin period cash flow 6.50M 1.35M 5.81M 10.92M 1.29M
End period cash flow 1.80M 6.50M 1.35M 5.81M 10.92M
Total cash from operating activities -10.45M -4.96M -5.88M -4.88M -3.99M
Issuance of capital stock 6.05M 4.21M 1.59M 0.00M 9.47M
Depreciation 0.09M 0.08M 0.15M 0.14M 0.15M
Other cashflows from investing activities -0.22M -0.15M - - -
Change to inventory - 0.00M 0.04M -0.00M 0.10M
Change to account receivables -0.21M -0.05M 0.03M -0.14M 0.19M
Other cashflows from financing activities 6.05M 6.11M -0.17M -0.18M 4.02M
Change to netincome - - - 2.60M -0.17M
Capital expenditures 0.02M 0.04M 0.17M 0.13M 0.08M
Change in working capital 0.20M 0.11M 0.14M -0.35M 0.06M
Stock based compensation 0.86M 0.49M 0.17M 0.75M 0.41M
Other non cash items 0.32M 0.17M 0.53M 1.96M 0.09M
Free cash flow -10.48M -5.00M -6.05M -5.01M -4.07M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
LEXX
Lexaria Bioscience Corp		 -0.30
6.47%		 4.34 - - 34.85 1.55 19.70 -7.22
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Lexaria Bioscience Corp

Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. The company's DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, epilepsy, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, and oral products; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

740 McCurdy Road, Kelowna, BC, Canada, V1X 2P7

250 765 6424

https://lexariabioscience.com

7

Name Title Year Born
Mr. Christopher A. Bunka Chairman & CEO 1962
Mr. John M. Docherty M.Sc. Pres & Director 1969
Mr. Gregory John Downey CMA, CPA CFO & Treasurer 1961
Vanessa Carle Head of Legal NA
Dr. Philip N. Ainslie Ph.D. Advisor & Consultant NA
Mr. John M. Docherty M.Sc. President & Director 1969
Mr. Nelson D. Cabatuan CPA Chief Financial Officer 1979
Kristin Hamilton Director of Operations NA
Mr. Richard C. Christopher CEO & Director 1970
Mr. John M. Docherty M.Sc. Chairman of the Scientific Advisory Board, Chief Scientific Officer, President & Director 1969

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…